Partnerships and collaborations

Our mission at xCures is to help patients and oncologists utilize any and all resources to fight advanced cancer. As a technology platform, we offer information and decision support directly to patients and oncologists. We also connect them with third-party resources from some of the best ‘patient first’ organizations to expand treatment options and services.

  • BioMed Valley Discoveries

    BioMed Valley Discoveries partnered with xCures to offer expanded access to ulixertinib, an ERK1/2 inhibitor for patients with advanced solid tumors no longer responding to standard of care. Learn More

    Visit BioMed Valley Discoveries

  • BioSpark

    BioSpark partnered with xCures to rapidly expand the scope of real-world oncology data and help patients and their physicians understand the best treatment options

    Visit BioSpark

  • Cellworks

    Cellworks partnered with xCures to advance predictive algorithms based on molecular systems biology and personalize oncology through multi-omic therapy biosimulation.

    Visit Cellworks

  • Cancer Commons

    Cancer Commons partners with xCures to provide a highly customized and personal experience for advanced cancer patients in need of treatment options.

    Visit Cancer Commons

  • CancerCompass

    CancerCompass is collaborating with xCures to allow consumers who contact CancerCompass to get immediate help as well as premium access to the xCures platform and services.

    Visit CancerCompass

  • COLONTOWN

    COLONTOWN collaborates with xCures to create a comprehensive precision medicine resource for COLONTOWN University.

    Visit COLONTOWN

  • Critical Path Institute

    The Critical Path Institute partnered with xCures to quickly abstract and structure clinical data to support drug repurposing studies in rare cancers.

    Visit Critical Path Institute

  • CureScience

    xCures’ partnership with CureScience serves to better identify specific patients and patient populations that may benefit from a particular test or treatment.

    Visit CureScience

  • DTRA

    xCures is part of a historic alliance of close to a hundred life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

    Visit DTRA

  • Endeavor

    Endeavor partnered with xCures to help screen and enroll patients who might be eligible for their PTCH1 clinical trial

    Visit Endeavor

  • Faeth

    Faeth partnered with xCures to launch a medical food clinical trial for treatment of patients with recent pancreatic adenocarcinoma or advanced PDAC and evaluate tolerability and satisfaction with the diet

    Visit Faeth

  • Fibro Fighters

    The FibroFighters Foundation is collaborating with xCures on an Observational Research Study to advance knowledge about FLHCC across the country. FLHCC is a rare cancer primarily affecting adolescents and young adults. Enroll Here

    Visit Fibro Fighters

  • Fibrolamellar Cancer Foundation

    The Fibrolamellar Cancer Foundation has partnered with xCures to drive fibrolamellar carcinoma (FLC) research and find treatment options for patients with FLC, a rare and often-fatal disease.

    Visit Fibrolamellar Cancer Foundation

  • Institute of Systems Biology

    The Institute of Systems Biology has partnered with xCures to develop innovative clinical trials to advance systems biology algorithms in glioblastoma and multiple myeloma.

    Visit Institute of Systems Biology

  • Massive Bio

    xCures partnered with Massive Bio to provide access to clinical trials for cancer patients regardless of their location and/or financial stability.

    Visit Massive Bio

  • Musella Foundation

    The Musella Foundation partnered with xCures and Cancer Commons to ensure that brain cancer patients get fast access to promising treatment options

    Visit Musella Foundation

  • Novocure

    Novocure has partnered with xCures to better understand the links between quality of life and treatment decisions, disease characteristics, and other factors for patients diagnosed with glioblastoma.

    Visit Novocure

  • Oblato

    Oblato partnered with xCures to offer OKN-007 through an expanded access program for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG)

    Visit Oblato

  • Oncoceutics

    Oncoceutics collaborated with xCures and Cancer Commons to implement an Expanded Access program for ONC201

    Visit Oncoceutics

  • Patient Record Scorecard

    xCures is a supporter of the Ciitizen Patient Record Scorecard that shows how medical record providers comply with the HIPAA Right of Access based on patient requests.

    Visit Patient Record Scorecard

  • POETIC

    xCures collaborates with POETIC, a non-profit organization that manages pediatric oncology early phase trials, to get children, adolescents, and young adults with cancer enrolled in expanded access programs of promising therapies. Learn More

    Visit POETIC

  • Prognos Health

    Prognos Health and xCures partnered to enable access to real-world oncology datasets and use continuous learning from every patient’s journey to drive insights and improve outcomes

    Visit Prognos Health

  • Tyra Biosciences

    Tyra partnered with xCures for a real-world biomarker study involving patients with FGFR-mutant bladder cancer. The study investigates tumor DNA to find treatment options if the disease worsens. Learn More

    Visit Tyra Biosciences